

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 819 433 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

21.01.1998 Bulletin 1998/04

(51) Int. Cl.⁶: **A61K 31/70**, A61K 31/505

// (A61K31/70, 31:35),

(A61K31/505, 31:35)

(21) Application number: 96120973.1

(22) Date of filing: 28.12.1996

(84) Designated Contracting States:

BE CH DE DK ES FR GB IT LI NL SE

(30) Priority: 18.07.1996 JP 206361/96

(71) Applicants:

- CANCER INSTITUTE (HOSPITAL) CHINESE ACADEMY OF MEDICAL SCIENCES
Chaoyang District, Beijing 100021 (CH)
- INSTITUTE OF MEDICAL BIOTECHNOLOGY,
CHINESE ACADEMY OF MEDICAL SCIENCES
Beijing 100050 (CH)
- MITSUI NORIN CO., LTD.
Tokyo (JP)

(72) Inventors:

- Cheng, Shu Jun
Chaoyang District, Beijing 100021 (JP)
- Wang, De Chang
Chaoyang District, Beijing 100021 (JP)
- Zhen, Yong Su
Tiantan, 100050, Beijing (JP)
- Nishino, Hoyoku
Hirakata-shi, Osaka-fu (JP)
- Hara, Yukihiro
Fujieda-shi, Shizuoka-ken (JP)

(74) Representative:

Türk, Gille, Hrabal, Leifert
Brucknerstrasse 20
40593 Düsseldorf (DE)

(54) **Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin**

(57) Method of strengthening an efficacy of cancer drug, especially anti-metabolite by administering said cancer drug to a patient with tea catechins and/or theaflavins.

EP 0 819 433 A2

Description

FIELD OF THE INVENTION

The present invention relates to a method of increasing the efficacy of cancer drugs, more specifically it relates to a method of increasing the efficacy of cancer drugs by combining and administering tea catechins and/or theaflavins at the same time as the administration of the cancer drugs.

BACKGROUND OF THE INVENTION

Cancer drugs administered to patients undergo oxidation in the body, and thus their effectiveness is reduced or eliminated. Also some types of cancer drugs produce active oxygen during metabolic processes and this can cause damage to the tissue of normal organs, causing some patients to suffer greatly from the side-effects.

With these points in mind we conducted research into a method of increasing the efficacy of cancer drugs, reducing side-effects thereof.

One of such methods which has been investigated is to administer an antioxidant at the same time as the administration of the cancer drug. However, up until now these attempts could not have been said to have reached a sufficient level of success.

SUMMARY OF THE INVENTION

The present inventors conducted extensive research into tea polyphenols such as tea catechins and theaflavins which are the dimers of catechins, and have reported that tea polyphenols have a strong antioxidative action, and free radical scavenging action.

As a result of extensive research into the applications of these functions of tea polyphenols, it was discovered that according to the administration of tea polyphenols at the same time as the administration of an anti-metabolite which is one type of cancer drug, the action of the cancer drug is strengthened, and thus the present invention was completed.


That is to say, the present invention relates to a method of increasing the efficacy of cancer drug by the addition of tea catechins and/or theaflavins to the cancer drug.

DETAILED DESCRIPTION OF THE INVENTION

The cancer drugs which are applicable to the method of the present invention are not restricted, and in particular chemical cancer drugs are given as preferable examples, but amongst these anti-metabolites are most suitable. Anti-metabolites are compounds which act antagonistically on the metabolism of purine base or pyrimidine base, such as cytarabine, methotrexate, 6-mercaptopurine, 5-fluorouracil etc., but among these cytarabine (1- β -D-arabinofuranosyl-cytosine: AraC) or methotrexate (4-amino-4-deoxy-10-methylfolic acid: MTX) are suitable.


The tea polyphenols used in the present invention may be tea catechins or theaflavins obtained by extraction of green tea leaves, black tea leaves etc. with water or organic solvents such as low-grade alcohol, acetone, ethyl acetate, and these may be further separated, purified and used individually or two or more may be combined and used.

Tea catechins are of the general formula I as shown below.




I

(where R¹ represents H or OH, and R² represents H or




Specifically tea catechins include epicatechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, gallo- catechin etc. (and their derivatives) and these may be used separately or a combination of two or more may be used. Among these, it is desirable that at least one of the following: epigallocatechin gallate, epicatechin gallate and epigallo- catechin, is used. In particular it is desirable that a tea catechin wherein epigallocatechin gallate is a main catechin component; as in for example, Polyphenon 100™ (Mitsui Norin Co., Ltd., Composition: (-)epicatechin, 10.8%, (-)epigal- locatechin 9.2%, (-)epicatechin gallate 6.5%, (-)epigallocatechin gallate 54.8%, (-) gallo catechin gallate 4.0%) or Polyphenon 60™ (Mitsui Norin Co., Ltd., Composition: (-)epigallocatechin 21.0%, (-)epicatechin, 7.3%, (-) epigallocate- chin gallate 29.2%, (-)epicatechin gallate 7.9%)

Theaflavins used in the present invention are of the general formula II as shown below.



(where R^3 and R^4 represents H or



and R^3 and R^4 may be the same or different).

Specifically, theaflavins include free theaflavins, theaflavin monogallate A, theaflavin monogallate B, theaflavin digallate etc. (and their derivatives), and these may be used individually, or two or more may be combined and used. In particular, desirable is a theaflavin containing theaflavin digallate as a main component; as in for example, Polyphenon TF™ (Mitsui Norin Co., Ltd., Composition: theaflavin 16.8%, theaflavin monogallate A 19.5%, theaflavin monogallate B 16.1%, theaflavin digallate 31.4%) may be used.

According to the present invention, the efficacy of cancer drugs can be strengthened by the addition of tea catechins and/or theaflavins at the same time as the administration of the above-mentioned cancer drugs.

The ratio of the cancer drug to the tea catechin and/or theaflavin should be decided according to the purpose of use, the method of administration of the drug and the type of cancer drug etc., but generally an amount of the cancer drug should be 1-20 mg/kg in case of intraperitoneal administration (i.p.), or more desirably, 5-15 mg/kg (i.p.), and an amount of the tea catechin and/or theaflavin should be 1-30 mg/kg in case of intraperitoneal administration (i.p.), or more desirably, 5-20 mg/kg (i.p.) or 100-1000 mg/kg in case of oral administration (p.o.).

According to the method of the present invention, to increase the efficacy of cancer drugs, tea catechins and/or theaflavins should be administered to patients in the ratios as described above. This mixture can be administered to patients in various forms. For example, it may be combined with a suitable excipient and can be used in an oral and/or non-oral form. A suitable amount of an auxiliary compound such as a lubricant, an emulsifier, a dispersing agent may be used.

As an oral administration, it may be in the form of a liquid, powder, tablet, capsule, granules etc., and in these cases the excipient used apart from water, could be sugars, starch, dextran, calcium phosphate, calcium carbonate, magnesium oxide, magnesium stearate, aluminium silicate, aluminium hydroxide, sodium carbonate, glycerol etc.

As a non-oral administration, it may be in the form of an injection, a drip, and ointment, and it could be mixed with suitable substances such as distilled water, physiological salt, plant oils such as olive oil, alcohol such as ethanol, and polyethylene glycol.

According to the method of the present invention, the efficacy of cancer drugs is strengthened without any side-effects since the cancer drug, in particular an anti-metabolite is used in combination with tea catechins and/or theaflavins.

EXAMPLES

The present invention will be explained by reference to the following examples.

5 Example 1:

1.5 x 10⁶ Leukemia L-1210 tumor cells were administered intraperitoneally to Balb/c mice (18-20 g), the mice were divided into 6 groups (10 mice in each group) and after 24 hours a fixed amount of each type of drug was intraperitoneally administered once a day for a period of seven days.

10 The average rate of survival of each group and the rate of survival of the drug administered group as compared to the control (T/C(%)) as well as long survival rate (over 60 days) were calculated. The results are shown in Table 1.

Table 1

Group	Dose (mg/kg)	Survival days average (day)±SD	T/C (%)	Number of survivors (over 60 days)
Control	—	16.1± 1.1		0/10
AraC	10	28.7±11.8	178	1/10
EGCg	10	26.8± 4.5	166	0/10
AraC + EGCg	10+10	60.0± 0	373 *	10/10
EGCg	20	12.8± 3.7	80	0/10
AraC + EGCg	10+20	37.3±20.1	232 *	4/10
SD: significant difference				

* P <0.01

30 As is evident from the table, administration of a combination of cytarabine (AraC) and epigallocatechin gallate (EGCg) significantly increased the survival rate of the mice, and moreover there was a high survival rate over 60 days. No side-effects were noticed.

35 Example 2:

This example was conducted in the same way as in Example 1 except that the amount of EGCg added was different. Results, as shown in Table 2, show that in this case too, the administration of a combination of cytarabine and epigallocatechin gallate increased the survival rate of the mice and significantly increased the survival rate over 60 days.

Table 2

Group	Dose (mg/kg)	Survival days average (day)±SD	T/C (%)	Number of survivors (over 60 days)
Control	—	17.8± 1.2		0/10
AraC	10	35.3±17.3	176	2/10
EGCg	5	21.0± 5.2	118	0/10
AraC + EGCg	10+5	49.2±17.7	275 *	7/10
EGCg	10	21.4± 4.7	120	0/10
AraC + EGCg	10+10	60.0± 0	337 *	10/10
SD: significant difference				

* P <0.01

Example 3:

This example was carried out in the same way as Example 1 except that the tumor cells used were Leukemia P388. Results are shown in Table 3. As is evident from the table, the survival rate of the mice increased and the survival rate over 60 days was significantly higher according to the administration of a combination of cytarabine and epigallocatechin gallate.

Table 3

Group	Dose (mg/kg)	Survival days average (day)±SD	T/C (%)	Number of survivors (over 60 days)
Control	—	15.4 ± 0.7		0/10
AraC	10	18.9 ± 1.4	123	0/10
EGCg	5	18.2 ± 1.3	118	0/10
AraC + EGCg	10+5	35.2 ± 21.3	229 *	4/10
EGCg	10	17.7 ± 1.8	115	0/10
AraC + EGCg	10+10	60.0 ± 0	390 *	10/10

SD: significant difference

* P < 0.01

Example 4:

KM mice (26-28 g) were each inoculated subcutaneously with 5×10^6 Sarcoma tumor cells (S-180), the mice were divided into 5 groups (10 mice in each group), and after 24 hours each drug was administered once a day for a period of seven days. According to the intraperitoneal administration 3 mg/kg of methotrexate (MTX) was administered, and 230 mg/kg or 460 mg/kg of epigallocatechin gallate (EGCg) was administered orally.

24 hours after administration of the last drug, the mice were killed, the weight of the tumors was calculated, and according to the extent of metabolic damage the efficacy of the drugs was calculated. Results are shown in Table 4. As is evident from the table, the weight of the tumors was significantly decreased by administration of a combination of methotrexate and epigallocatechin gallate.

Table 4

Group	Number of mice	Dose mg/kg	Tumor weight g±SD	Inhibition (%)	P value
Control	10	—	2.13±0.58	—	—
MTX	10	3.0 i.p. × 7	1.00±0.18	53.1	<0.01 [#]
EGCg	10	230 p.o. × 7	1.76±0.72	17.4	>0.05 [#]
MTX + EGCg	10	3.0 i.p. × 7	0.93±0.31	56.3	>0.05*
		230 p.o. × 7			
MTX + EGCg	10	3.0 i.p. × 7	0.82±0.46	61.5	>0.05*
		460 p.o. × 7			

i.p. : intraperitoneal administration p.o. : oral administration

SD: significant difference

[#]: compare with control

*: compare with MTX

Claims

1. A method of strengthening an efficacy of cancer drug which comprises administrating said cancer drug to a patient with tea catechin and/or theaflavin.
2. The method of Claim 1 wherein the cancer drug is an antimetabolite.
3. The method of Claim 1 wherein the cancer drug is cytarabine or methotrexate.
4. The method of Claim 1 wherein the tea catechin consists of epigallocatechin gallate as a main component.
5. The method of Claim 1 wherein the tea catechin contains at least one of the following: epigallocatechin gallate, epicatechin gallate, and epigallocatechin.
6. The method of Claim 1 wherein the theaflavin consists of theaflavin digallate as a main component.
7. A cancer drug composition having improved efficacy which consists essentially of cancer drug and tea catechin and/or theaflavin.
8. The cancer drug of Claim 7 wherein the cancer drug is in an amount of 1-20 mg/kg in case of intraperitoneal administration and the tea catechin is in an amount of 5-20 mg/kg in case of intraperitoneal administration.
9. The cancer drug of Claim 7 wherein the cancer drug is in an amount of 1-20 mg/kg in case of intraperitoneal administration and the theaflavin is in an amount of 5-20 mg/kg in case of intraperitoneal administration.
10. The cancer drug of Claim 7 wherein the cancer drug is in an amount of 1-20 mg/kg in case of intraperitoneal administration and the tea catechin and/or theaflavin is in an amount of 100-1000 mg/kg in case of oral administration.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 819 433 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
12.05.1999 Bulletin 1999/19

(43) Date of publication A2:
21.01.1998 Bulletin 1998/04

(21) Application number: 96120973.1

(22) Date of filing: 28.12.1996

(51) Int. Cl.⁶: **A61K 31/70**, A61K 31/505
// (A61K31/70, 31:35),
(A61K31/505, 31:35)

(84) Designated Contracting States:
BE CH DE DK ES FR GB IT LI NL SE

(30) Priority: 18.07.1996 JP 206361/96

(71) Applicants:
• **CANCER INSTITUTE (HOSPITAL) CHINESE
ACADAMY OF MEDICAL SCIENCES**
Chaoyang District, Beijing 100021 (CH)
• **INSTITUTE OF MEDICINAL BIOTECHNOLOGY,
CHINESE ACADAMY OF MEDICAL SCIENCES**
Beijing 100050 (CH)
• **MITSUI NORIN CO., LTD.**
Tokyo (JP)

(72) Inventors:
• **Cheng, Shu Jun**
Chaoyang District, Beijing 100021 (JP)
• **Wang, De Chang**
Chaoyang District, Beijing 100021 (JP)
• **Zhen, Yong Su**
Tiantan, 100050, Beijing (JP)
• **Nishino, Hoyoku**
Hirakata-shi, Osaka-fu (JP)
• **Hara, Yukihiro**
Fujieda-shi, Shizuoka-ken (JP)

(74) Representative:
Türk, Gille, Hrabal
Patentanwälte - European Patent Attorneys,
Brucknerstrasse 20
40593 Düsseldorf (DE)

(54) **Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin**

(57) Method of strengthening an efficacy of cancer drug, especially anti-metabolite by administrating said cancer drug to a patient with tea catechins and/or theaflavins.

EP 0 819 433 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 12 0973

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	ZHEN Y.-S. ET AL: "Novel nucleoside transport inhibitors of natural origin." ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1995) 370/- (779-782). ISSN: 0065-2598 CODEN: AEMBAP, XP002096277 United States	1-7	A61K31/70 A61K31/505
Y	* page 780, paragraph 7 *	8-10	/(A61K31/70, 31:35), (A61K31/505, 31:35)
X	ZHEN Y. ET AL: "Green tea extract inhibits nucleoside transport and potentiates the antitumor effect of antimetabolites." CHINESE MEDICAL SCIENCES JOURNAL, (1991) 6/1 (1-5). ISSN: 1001-9294 CODEN: CMSJEP, XP002096278 China	1-7	
Y	* page 1; tables 1-3 *	8-10	
Y	KOMORI, ATSUMASA ET AL: "Anticarcinogenic activity of green tea polyphenols." JAPANESE JOURNAL OF CLINICAL ONCOLOGY, (1993) VOL. 23, NO. 3, PP. 186-190 ISSN: 0368-2811., XP002096279 * the whole document *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K
Y	US 5 391 568 A (CHUNG FUNG L) 21 February 1995 * the whole document *	1-10	
Y	WO 95 23607 A (ROYAL FREE HOSP SCHOOL MED ; HAMILTON MILLER JEREMY MARCUS (GB)) 8 September 1995 * abstract *	1-10	
A	DE 40 26 683 A (BOUZEK PAULINA) 27 February 1992 * column 1, line 28 - line 32 *	1-10	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 11 March 1999	Examiner Foerster, W
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 92 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 96 12 0973

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-03-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5391568	A	21-02-1995	NONE	
WO 9523607	A	08-09-1995	EP 0748224 A	18-12-1996
			JP 9509677 T	30-09-1997
			US 5879683 A	09-03-1999
DE 4026683	A	27-02-1992	NONE	

